Department of Engineering Chemistry, College of Engineering, Koneru Lakshmaiah Education Foundation, Vaddeswaram, Andhra Pradesh, 522302, India.
Medicinal Chemistry Division, Aragen Life Sciences Pvt. Ltd, Mallapur (Formerly called as GVK Biosciences PVT. Ltd), Hyderabad, Telangana, 500076, India.
Chem Biodivers. 2022 Dec;19(12):e202200681. doi: 10.1002/cbdv.202200681. Epub 2022 Nov 23.
In this article, we prepared a novel series of 1,3,4-oxadiazoles containing chalcone analogs via replacement of phthalazine which had increased antibacterial activity and the final compounds were confirmed by proton, carbon nuclear magnetic resonance spectroscopy, infrared and mass spectral analysis. Two sets of 1,3,4-oxadiazoles like 2-methyl-5-substitutedbenzylthio-1,3,4-oxadiazolyl-4-methylphthalazine-2-ones (3a-f), (E)-substituted phenyl acryloylphenyl-4-methyl-1-oxophthalazine-1,3,4-oxadiazolylthioacetamides (5a-f) were designed, synthesized and evaluated for their in vitro antibacterial potency against different Gram-(+ve), Gram-(-ve) microorganisms and fungal strains. The synthesized 4-methyl-2-{[5-({[2-(trifluoromethyl)phenyl]methyl}sulfanyl)-1,3,4-oxadiazol-2-yl]methyl}phthalazin-1(2H)-one (3c), 4-methyl-2-[(5-{[(4-nitrophenyl)methyl]sulfanyl}-1,3,4-oxadiazol-2-yl)methyl]phthalazin-1(2H)-one (3d), N-(4-{(2E)-3-[2-(dimethylamino)phenyl]prop-2-enoyl}phenyl)-2-({5-[(4-methyl-1-oxophthalazin-2(1H)-yl)methyl]-1,3,4-oxadiazol-2-yl}sulfanyl)acetamide (5d), and N-{4-[(2E)-3-(3-hydroxy-4-methoxyphenyl)prop-2-enoyl]phenyl}-2-({5-[(4-methyl-1-oxophthalazin-2(1H)-yl)methyl]-1,3,4-oxadiazol-2-yl}sulfanyl)acetamide (5e) displayed improved activity with MICs 1.41, 0.87, 2.16, 0.89 μg/mL as compared to the standard drugs rifamycin, ciprofloxacin, fluconazole (MIC=1.52, 1.94, 3.02 μg/mL). The prepared compounds were also analyzed with better target binding towards bacterial bioavailability, 5e exhibited highest bonds with amino acids ArgA , LysA , LysA , ArgA , AspA , IleA , HisA and having docking energy -8.68 Kcal/mol and dissociation constant 432.48 nM, respectively. These compounds were further evaluated for their ADMET and physicochemical properties by using SwissADME.
在本文中,我们通过取代具有增加抗菌活性的酞嗪,制备了一系列新型 1,3,4-噁二唑类查耳酮类似物,最终化合物通过质子、碳核磁共振波谱、红外和质谱分析得到证实。设计并合成了两组 1,3,4-噁二唑类化合物,如 2-甲基-5-取代苄硫基-1,3,4-噁二唑基-4-甲基酞嗪-2-酮(3a-f)和(E)-取代苯基丙烯酰基-苯基-4-甲基-1-氧代酞嗪-1,3,4-噁二唑基硫代乙酰胺(5a-f),并对其进行了体外抗菌活性评价,以评估它们对不同革兰氏阳性菌(+ve)、革兰氏阴性菌(-ve)微生物和真菌菌株的抑制作用。合成的 4-甲基-2-[[5-[[(2-(三氟甲基)苯基)甲基]硫代]-1,3,4-噁二唑-2-基]甲基]酞嗪-1(2H)-酮(3c)、4-甲基-2-[(5-[[(4-硝基苯基)甲基]硫代]-1,3,4-噁二唑-2-基]甲基]酞嗪-1(2H)-酮(3d)、N-(4-[[(2E)-3-[2-(二甲基氨基)苯基]丙-2-烯酰基]苯基]-2-[[5-(4-甲基-1-氧代酞嗪-2(1H)-基)甲基]-1,3,4-噁二唑-2-基]硫代)乙酰胺(5d)和 N-{4-[[(2E)-3-(3-羟基-4-甲氧基苯基)丙-2-烯酰基]苯基}-2-[[5-(4-甲基-1-氧代酞嗪-2(1H)-基)甲基]-1,3,4-噁二唑-2-基]硫代)乙酰胺(5e)与标准药物利福霉素、环丙沙星、氟康唑(MIC=1.52、1.94、3.02μg/mL)相比,显示出改善的活性,MIC 值分别为 1.41、0.87、2.16、0.89μg/mL。还通过与细菌生物利用度的更好的靶标结合对制备的化合物进行了分析,5e 与氨基酸 ArgA、LysA、LysA、ArgA、AspA、IleA、HisA 具有最高的键合,结合能为-8.68Kcal/mol,解离常数为 432.48nM。通过使用 SwissADME 进一步评估了这些化合物的 ADMET 和物理化学性质。